Effective preventive central nervous system therapy with extended triple intrathecal therapy and the modified ALL-BFM 86 chemotherapy program in an enlarged non-high risk group of children and adolescents with non-B-cell acute lymphoblastic leukemia. The Israel National Study Report

Cancer

Volumn 88, Issue 1, 2000, Pages 205-216

  Stark, Batia ^a,b   Sharon, Rivka ^c   Rechavi, Gideon ^b,d   Attias, Dina ^e   Ballin, Ami ^b,f   Cividalli, Gabriel ^g   Burstein, Yoav ^b   Sthoeger, Dalia ^h,i   Abramov, Ayala ⁱ   Zaizov, Rina ^a,b  

^a SCHNEIDER CHILDREN S MEDICAL CENTER OF ISRAEL   (Israel)

^b TEL AVIV UNIVERSITY   (Israel)

^c RAMBAM MEDICAL CENTER   (Israel)

^d SHEBA MEDICAL CENTER   (Israel)

^e BNAI ZION MEDICAL CENTER   (Israel)

^f WOLFSON MEDICAL CENTER   (Israel)

^g HADASSAH HEBREW UNIVERSITY MEDICAL CENTER   (Israel)

^h KAPLAN MEDICAL CENTER   (Israel)

ⁱ HEBREW UNIVERSITY   (Israel)

Author keywords

Central nervous system prophylaxis; Childhood acute lymphoblastic leukemia treatment; Extended triple intrathecal

Indexed keywords

ASPARAGINASE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; ETOPOSIDE; FOLINIC ACID; HYDROCORTISONE; MERCAPTOPURINE; METHOTREXATE; VINCRISTINE;

ACUTE LYMPHOBLASTIC LEUKEMIA; ARTICLE; BACTERIAL INFECTION; BRAIN HEMORRHAGE; CANCER COMBINATION CHEMOTHERAPY; CANCER PREVENTION; CANCER RECURRENCE; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD LEUKEMIA; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; ENCEPHALITIS; FEMALE; FOLLOW UP; HUMAN; INFANT; ISRAEL; MAJOR CLINICAL STUDY; MALE; NEUROTOXICITY; PNEUMONIA; PRIORITY JOURNAL; SURVIVAL RATE;

ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CHILD; CHILD, PRESCHOOL; CYTARABINE; FEMALE; HUMANS; HYDROCORTISONE; INFANT; INJECTIONS, SPINAL; ISRAEL; LEUKEMIA, LYMPHOCYTIC, ACUTE, L1; LIFE TABLES; MALE; METHOTREXATE; RADIOTHERAPY, ADJUVANT; RISK; TREATMENT OUTCOME;

EID: 0033979535     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1097-0142(20000101)88:1<205::AID-CNCR28>3.0.CO;2-7     Document Type: Article

References (62)

1. Pinkel D, Woo S. Prevention and treatment of meningeal leukemia in children. Blood 1994;84:355-66.
2. Nesbit ME, Sather H, Robison LL, Donaldson M, Littman P, Ortega JA, et al. Sanctuary therapy: a randomized trial of 724 children with previously untreated acute lymphoblastic leukemia. A report from the Children's Cancer Study Group. Cancer Res 1982;42:674-80.
3. Rivera GK, Pinkel D, Simone JV, Hancock ML, Crist WM. Treatment of acute lymphoblastic leukemia. 30 years' experience at St. Jude Children's Research Hospital. N Engl J Med 1993;329:1289-95.
4. Price RA. Therapy related central nervous system diseases in children with acute lymphocytic leukemia. In: Mastrangelo R, Poplack DG, Riccardi R, editors. Central nervous system leukemia: prevention and treatment. Martinus Nijhoff Publishers, 1983:71-81.
5. Tiberin P, Maor E, Zaizov R, Cohen IJ, Hirsch M, Yosefovich T, et al. Brain sarcoma of meningeal origin after cranial irradiation in childhood acute lymphocytic leukemia. J Neurosurg 1984;61:772-6.
6. Ochs JJ. Neurotoxicity due to central nervous system therapy for childhood leukemia. Am J Pediatr Hematol Oncol 1989;11:93-105.
7. Meadows AT, Gordon J, Massari DJ, Littman P, Fegusson J, Moss Karen. Declines in IQ scores and cognitive dysfunctions in children with acute lymphocytic leukaemia treated with cranial irradiation. Lancet 1981;2:1015-8.
8. Packer RJ, Meadows AT, Rorke LB, Goldwein JL, D'Angio G. Long term sequelae of cancer treatment on the central nervous system in childhood. Med Pediatr Oncol 1987;15:241-53.
9. Green DM, Freeman AI, Sather HN, Sallen SE, Nesbit ME, Cassady JR, et al. Comparison of three methods of central-nervous-system prophylaxis in childhood acute lymphoblastic leukaemia. Lancet 1980;1:1398-402.
10. Sullivan MP, Chen T, Dyment PG, Hvizdala E, Steuber P. Equivalence of intrathecal chemotherapy and radiotherapy as central nervous system prophylaxis in children with acute lymphatic leukemia: a Pediatric Oncology Group study. Blood 1982;60:948-58.
11. Freeman AI, Boyett JM, Glicksman AS, Brecher ML, Leventhal BG, Sinks LF, et al. Intermediate-dose methotrexate versus cranial irradiation in childhood acute lymphoblastic leukemia: a ten-year follow-up. Med Pediatr Oncol 1997;28: 98-107.
12. Blaney SM, Poplack DG. Central nervous system leukemia. Curr Opin Oncol 1996;8:13-9.
13. Bleyer A. CNS chemoradiotherapy of childhood leukemia: the plot thickens but the ending bodes well [editorial]. J Clin Oncol 1995;13:2480-2.
14. Stark B, Abramov A, Attias D, Balin A, Barak Y, Goshen Y, et al. Successful central nervous system prophylaxis without radiotherapy in childhood acute lymphoblastic leukemia (ALL): Israel National Studies (INS 1984, 1989). In: Büchner et al., editors. Acute leukemias IV. Prognostic factors. Berlin: Springer-Verlag, 1994;359-65.
15. Stark B, Abramov A, Attias D, Balin A, Burstein Y, Chividalli G, et al. Extended intrathecal triple therapy for preventing CNS relapse in non very high risk childhood acute lymphoblastic leukemia treated with the Israeli Studies INS-84 and INS-89 (modified BFM 86) [abstract 1087]. Proc Am Soc Clin Oncol 1996;15:367.
16. Riehnn H, Gadner H, Henze G, Kornhuber B, Lampert F, Niethammer D, et al. Results and significance of six randomized trials in four consecutive ALL-BFM studies. Haematol Blood Transfusion 1990;33:439-50.
17. Niemeyer CM, Hitchcock-Bryan S, Sallan SE. Comparative analysis of treatment programs for childhood acute lymphoblastic leukemia. Semin Oncol 1985;12:122-30.
18. Rivera GK, Mauer AM. Controversies in the management of childhood acute lymphoblastic leukemia: treatment intensification, CNS leukemia, and prognostic factors. Semin Hematol 1987;24:12-26.
19. Gaynon PS, Bleyer WA, Steinherz PG, Finklestein JZ, Littman PS, Miller DR, et al. Modified BFM therapy for children with previously untreated acute lymphoblastic leukemia and unfavorable prognostic features. Report of Children's Cancer Study Group Study CCG-193P. Am J Pediatr Hematol Oncol 1988;10:42-50.
20. Reiter A, Schrappe M, Ludwig W-D, Hiddenmann W, Sauter S, Henze G, et al. Chemotherapy in 998 unselected childhood acute lymphoblastic leukemia patients, Results and conclusions of the multicenter trial ALL-BFM 86. Blood 1994;84:3122-33.
21. Moe PJ, Seip M, Finne H, Kolmannskog S. Methotrexate infusions in poor prognosis acute lymphoblastic leukemia in children: I. The Norwegian methotrexate study in acute lymphoblastic leukemia in childhood, August 1975-December 1980. Med Pediatr Oncol 1986;14:187-8.
22. 2 in children with acute lymphoblastic leukemia. Cancer 1987; 60:5-13.
23. Abromowitch M, Ochs J, Pui C-H, Fairclough D, Murphy SB, Rivera GK. Efficacy of high dose methotrexate in childhood acute lymphocytic leukemia: analysis by contemporary risk classifications. Blood 1988;71:866-9.
24. Welte K, Reiter A, Mempel K, Pfetsch M, Schwab G, Schrappe M, et al. A randomized Phase-III study of the efficacy of granulocyte colony-stimulating factors in children with high-risk acute lymphoblastic leukemia. Blood 1996;87:3143-50.
25. 9/L. J Clin Oncol 1987;5:1015-21.
26. Blume KG, Forman SJ, O'Donnell MR, Doroshow JH, Krance RA, Nademanee AP, et al. Total body irradiation and high-dose etoposide: a new preparatory regimen for bone marrow transplantation in patients with advanced hematologic malignancies. Blood 1987;69:1015-20.
27. Bennet JM, Catovsky D, Daniel MT, Flandrin G, Glaton DAG, Gralnick HR, et al. Proposals for the classification of the acute leukemias. French-American-British (FAB) co-operative group. Br J Haematol 1976;33:451-8.
28. Pui C-H, Behm FG, Crist WM. Clinical and biologic relevance of immunologic marker studies in childhood acute lymphoblastic leukemia [review article]. Blood 1993;82:343-62.
29. Rothe G, Schmitz G, Adorf D, Barlage S, Gramatzki M, Hanenberg H, et al. Consensus protocol for the flow cytometric immunophenotyping of hematopoietic malignancies. Leukemia 1996;10:877-95.
30. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457-81.
31. Mantel N. Evaluation of survival data and two new rank order statistics arising in its consideration. Cancer One-mother Rep 1966;50:163-70.
32. SPSS, Inc. SPSS base 7.5 for Windows: user's guide. Chicago, IL: SPSS, Inc., 1997.
33. Cox DR. Regression models and life tables. J R Stat Soc 1972;34:187-220.
34. Schrappe M, Reiter A, Henze G, Graf N, Niemeyer C, Riehm H. Effective CNS protection in ALL without and with reduced cranial irradiation in four BFM trials [abstract O-26]. Med Pediatr Oncol 1995;25:240.
35. Conter V, Schrappe M, Aricó M, Reiter A, Rizzari C, Dördelmann M, et al. Role of cranial radiotherapy for childhood T-cell acute lymphoblastic leukemia with high WBC count and good response to prednisone. J Clin Oncol 1997;15: 2786-91.
36. Shuster JJ, Wacker P, Pullen J, Humbert J, Land VJ, Mahoney DH Jr., et al. Prognostic significance of sex in childhood B-precursor acute lymphoblastic leukemia: a Pediatric Oncology Group study. J Clin Oncol 1998;16:2854-63.
37. Pui CH, Boyett JM, Relling MV, Harrison PL, Rivera GK, Behm FG, et al. Sex differences in prognosis for children with acute lymphoblastic leukemia. J Clin Oncol 1999;17: 818-24.
38. Conter V, Aricó M, Valsecchi MG, Rizzari C, Testi AM, Messina C, et al. Extended intrathecal methotrexate may replace cranial irradiation for prevention of CNS relapse in children with intermediate-risk acute lymphoblastic leukemia treated with Berlin-Frankfurt-Münster-based intensive chemotherapy. J Clin Oncol 1995;13:2497-502.
39. Tubergen DG, Gilchrist GS, O'Brien RT, Coccia PF, Sather HN, Waskerwitz MJ, et al. Prevention of CNS disease in intermediate-risk acute lymphoblastic leukemia: comparison of cranial radiation and intrathecal methotrexate and the importance of systemic therapy: a Children's Cancer Group report. J Clin Oncol 1993;11:520-26.
40. Nachman J, Sather HN, Cherlow JM, Sensel MG, Gaynon PS, Lukens JN, et al. Response of children with high-risk acute lymphoblastic leukemia treated with and without cranial irradiation: a report from the Children's Cancer Group. J Clin Oncol 1998;16:920-30.
41. Veerman AJP, Hählen K, Kamps WA, Van Leeuwen EF, De Vaan GAM, Solbu G, et al. High cure rate with a moderately intensive treatment regimen in non-high-risk childhood acute lymphoblastic leukemia: results of protocol ALL VI from the Dutch Childhood Leukemia Study Group. J Clin Oncol 1996;14:911-8.
42. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Pui C-H, et al. Conventional compared with individualized chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med 1998;338:499-505.
43. Masson E, Relling MV, Synold TW, Lui Q, Schuetz JD, Sandlund JT, et al. Accumulation of methotrexate polyglutamates in lymphoblasts is a determinant of antileukemic effects in vivo. A rationale for high-dose methotrexate. J Clin Invest 1996;97:73-80.
44. Balls FM, Poplack DG. Central nervous system pharmacology of antileukemic drugs. Am J Pediatr Hematol Oncol 1989;11:74-86.
45. 2 methotrexate. Leukemia Lymphoma 1994;14:141-4.
46. Matherly LH, Taub JW. Methotrexate pharmacology and resistance in childhood acute lymphoblastic leukemia. Leukemia Lymphoma 1996;21:359-68.
47. Thyss A, Milano G, Etienne MC, Paquis P, Roche JL, Grelier P, et al. Evidence of CSF accumulation of 5-methyltetrahydrofolate during repeated courses of methotrexate plus folinic acid rescue. Br J Cancer 1989;59:627-30.
48. Borsi JD, Wesenberg F, Stokland T, Moe PJ. How much is too much? Folinic acid rescue dose in children with acute lymphoblastic leukaemia. Eur J Cancer 1991;27:1006-9.
49. Mahoney DH Jr., Camitta BM, Leventhal BG, Shuster JJ, Civin CJ, Ganick DJ, et al. Repetitive low dose oral methotrexate and intravenous mercaptopurine treatment for patients with lower risk B-lineage acute lymphoblastic leukemia. Cancer 1995;75:2623-31.
50. Mahoney DH Jr., Shuster JJ, Nitschke R, Lauer SJ, Steuber CP, Winick N, et al. Acute neurotoxicity in children with B-precursor acute lymphoid leukemia: an association with intermediate-dose intravenous methotrexate and intrathecal triple therapy - a Pediatric Oncology Group study. J Clin Oncol 1998;16:1712-22.
51. Rubnitz JE, Relling MV, Harrison PL, Sandlund JT, Ribeiro RC, Rivera GK, et al. Transient encephalopathy following high-dose methotrexate treatment in childhood acute lymphoblastic leukemia. Leukemia 1998;12:1176-81.
52. Mulhern RK, Fairclough D, Ochs J. A prospective comparison of neuropsychologic performance of children surviving leukemia who received 18-Gy, 24-Gy, or no cranial irradiation. J Clin Oncol 1991;9:1348-56.
53. Butler RW, Hill JM, Steinherz PG, Meyers PA, Finlay JI. Neuropsychologic effects of cranial irradiation, intrathecal methotrexate, and systemic methotrexate in childhood cancer. J Clin Oncol 1994;12:2621-9.
54. Copeland DR, Moore BD III, Francis DJ, Jaffe N, Culbert SJ. Neuropsychologic effects of chemotherapy on children with cancer: a longitudinal study. J Clin Oncol 1996;14:2826-35.
55. Österlundh G, Bjure J, Lannering B, Kjellmer I, Uvebrant P, Ildikó M. Studies of cerebral blood flow in children with acute lymphoblastic leukemia: case reports of six children treated with methotrexate examined by single photon emission computed tomography. J Pediatr Hematol Oncol 1997; 19:28-34.
56. Stine KC, Saylors RL, Sawyer JR, Bewcton DL. Secondary acute myelogenous leukemia following safe exposure to etoposide. J Clin Oncol 1997;15:1583-6.
57. Soslow RA, Davis RE, Warnke RA, Cleary ML, Kamel OW. True histiocytic lymphoma following therapy for lymphoblastic neoplasms. Blood 1996;87:5207-12.
58. Antillon F, Kaste SC, Jenkins JJ, Shurtleff SA, Merchant TE, Downing JR, et al. Primitive neuroectodermal tumor of bone as a second malignant neoplasm in a child previously treated for acute lymphoblastic leukemia. J Pediatr Hematol Oncol 1997;19:473-6.
59. Pui C-H, Ribeiro RC, Hancock ML, Rivera GK, Evans WE, Raimondi SC, et al. Acute myeloid leukemia in children treated with epipodophyllotoxins for acute lymphoblastic leukemia. N Engl J Med 1991;325:1682-7.
60. Pui C-H, Relling MV, Behm FG, Hancock ML, Boyett JM, Raimondi SC, et al. L-asparaginase may potentiate the leukemogenic effect of the epipodophyllotoxins. Leukemia 1995;9:1680-4.
61. Lorico A, Boiocchi M, Rappa G, Sen S, Erba E, D'Incalci M. Increase in topoisomerase-II-mediated DNA breaks and cytotoxicity of VP16 in human U937 lymphoma cells pre-treated with low doses of methotrexate. Int J Cancer 1990; 45:156-62.
62. Holden SA, Teicher BA, Robinson MF, Northey D, Rosowsky A. Antifolates can potentiate topoisomerase II inhibitors in vitro and in vivo. Cancer Chemother Pharmacol 1995; 36:165-71.